Business Context and Reporting Period
Company: Anteris Technologies Global Corp. (AVR)
Filing Type: Form 8-K (Current Report)
Date of Report: January 20, 2026
Reporting Period: Event date January 20, 2026; Expected Closing Date January 22, 2026.
Context: The Company, an emerging growth company focused on structural heart therapeutics, announced a significant capital raise via a public underwritten offering and a private placement to fund clinical trials and manufacturing expansion.
Key Financial Metrics and Capital Structure
Capital Raised (Estimated Gross Proceeds): Approximately $320 million total.
Public Offering Details:
- Shares Sold: 34,782,609 shares (Firm) + 5,217,391 shares (Optional, fully exercised).
- Price per Share: $5.75.
- Underwriters: Barclays Capital Inc., Wells Fargo Securities, LLC, and Cantor Fitzgerald & Co.
- Investor: Covidien Group S.à r.l. (wholly owned subsidiary of Medtronic plc).
- Shares Sold: 15,652,173 shares.
- Price per Share: $5.75.
- Gross Proceeds: Approximately $90.0 million.
- Execution of the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial (PARADIGM Trial).
- Expansion of manufacturing capabilities.
- Research and development for v2vmedtech, inc.
- Working capital and general corporate purposes.
Note: This filing does not provide historical revenue, profit, cash flow, or debt metrics. It focuses solely on the new capital raise.
Material Changes and Agreements
The primary material change is the entry into definitive agreements for a $320 million capital raise. Key contractual terms include:
- Lock-up Period: Executive officers and directors are subject to a 90-day lock-up period regarding sales of Common Stock.
- Investor Rights (Medtronic/Covidien):
- Participation Rights: Right to maintain ownership percentage in future equity issuances (if holding >75% of PIPE shares).
- Transfer Restrictions: Prohibited from transferring shares until May 22, 2027; volume limitations apply until January 22, 2029.
- Standstill: Investor cannot acquire additional securities or pursue extraordinary transactions until May 22, 2027.
- Board Observer: Right to designate one non-voting board observer until specific termination events occur.
- Right to Negotiate: If an acquisition proposal is received prior to FDA Class III device approval, the Company must negotiate in good faith with the Investor.
- Registration Rights: Company must file a resale registration statement within 18 months. Liquidated damages of 1.0% per 30-day period (capped at 5.0%) apply if registration is delayed.
Outlook, Risks, and Management Commentary
Management Outlook: The Company intends to use the net proceeds to advance its clinical strategy, specifically the PARADIGM Trial for patients with severe aortic stenosis, and to expand manufacturing. The capital raise is viewed as a catalyst for the next stage of growth.
Risks and Contingencies:
- Forward-Looking Statements: The filing contains forward-looking statements regarding the closing date and use of proceeds, which are subject to risks and uncertainties.
- Closing Conditions: The transaction is subject to the satisfaction of customary closing conditions.
- Regulatory Risk: Success depends on the FDA approval of the Class III device, which triggers specific negotiation rights for the Investor.
Investor Verification Checklist
- Closing Confirmation: Verify the actual closing date (expected Jan 22, 2026) and final net proceeds after deducting underwriting discounts and fees.
- Dilution Impact: Calculate the total share count increase (approx. 55.6 million new shares) and its impact on existing shareholder ownership.
- Medtronic Relationship: Review the specific terms of the "Collaboration" clause to understand potential future co-development or co-commercialization opportunities.
- Lock-up Expiry: Note the 90-day lock-up expiration for insiders and the May 2027 transfer restriction for the PIPE investor.
- Registration Rights Compliance: Monitor the filing of the Resale Registration Statement within the 18-month window to avoid liquidated damages.